宜明昂科2024年业绩:收入增至7414.9万元 年内亏损降至3.17亿元

财中社
26 Mar

3月26日,宜明昂科(01541)发布年度业绩公告,截至2024年12月31日止年度,公司的收入为7414.9万元,相较于2023年,增加了7370万元,主要由于与AxionBio, Inc.达成的授权及合作协议所产生的首付款及近期付款。此外,公司的研发开支由2023年的2.92亿元增加至2024年的3.23亿元,增幅为10.6%,主要原因是临床前及CMC开支的增加以及薪资费用的上升。在管理层讨论...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10